Who are tumor necrosis factor inhibitors (TNFi)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Elrexfio, Trulance, Lymphostat B, Prolia, Simponi, Humira.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tumor-necrosis-factor-inhibitors-tnfi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

tumor necrosis factor inhibitors (TNFi) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

tumor necrosis factor inhibitors (TNFi) (tumor-necrosis-factor-inhibitors-tnfi) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: biologic. Area: Oncology.

marketed biologic tumor necrosis factor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

tumor necrosis factor inhibitors (TNFi) (tumor-necrosis-factor-inhibitors-tnfi) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
tumor necrosis factor inhibitors (TNFi) TARGET	tumor-necrosis-factor-inhibitors-tnfi	Pfizer	marketed	biologic	tumor necrosis factor
Elrexfio	elranatamab-bcmm	Pfizer	marketed		Tumor necrosis factor receptor superfamily member 17	2023-01-01
Trulance	PLECANATIDE	Salix	marketed	Guanylate Cyclase-C Agonist [EPC]	Tumor necrosis factor	2017-01-01
Lymphostat B	BELIMUMAB	Human Genome Sciences Inc.	marketed	B Lymphocyte Stimulator-specific Inhibitor [EPC]	Tumor necrosis factor ligand superfamily member 13B	2011-01-01
Prolia	DENOSUMAB	Amgen	marketed	RANK Ligand Inhibitor [EPC]	Tumor necrosis factor ligand superfamily member 11	2010-01-01
Simponi	GOLIMUMAB	Centocor Ortho Biotech Inc	marketed	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	2009-01-01
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01

Recent regulatory actions (last 90 days)

2026-02-19 — Elrexfio · FDA · approved · US · Pfizer

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (biologic class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tumor necrosis factor inhibitors (TNFi) — Competitive Intelligence Brief. https://druglandscape.com/ci/tumor-necrosis-factor-inhibitors-tnfi. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab